# Title

 Food and Drugs. PART 316â€”ORPHAN DRUGS


# ID

 CFR-2018-title21-vol5.Pt. 316


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                              |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['greater', 'more than', 'before', 'after', 'prior to', 'equal to', 'less than', 'within', 'later than']                                                                                                                                            |
| Duration    | ['7.0 year', '14.0 month', '1.0 year', '60.0 day', '90.0 day']                                                                                                                                                                                      |
| Condition   | ['subject to', 'until', 'where', 'when', 'unless', 'if']                                                                                                                                                                                            |
| Entities    | ['U.S', 'Animal', 'United States', 'Cost', 'Scope', 'Guidance', 'Documents, Government Printing Office, Washington, DC', 'Purpose', 'Deficiency', 'Treatment', 'Food', 'Refusal', 'Rm', 'Change', 'Availability', 'Address', 'Annual', 'Amendment'] |
| Date        | ['2013-08-12']                                                                                                                                                                                                                                      |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                           |
|:--------------|:------------------------------------------------------------------------------------------------------------------|
| greater       | endpoint in adequate and well controlled clinical trials). greater                                                |
| greater       | that is associated with relatively frequent adverse effects. greater                                              |
| greater       | necessary; or (iii) In unusual cases, where neither greater  safety nor                                           |
| greater       | necessary; or (iii) In unusual cases, where neither greater  safety nor                                           |
| prior to      | studies be submitted to FDA for agency review. prior to                                                           |
| within        | or (2) Withdraw the request for written recommendations. within                                                   |
| after         | (c) Within 90 days  after the date of a letter from FDA requesting                                                |
| within        | FDA will consider a sponsor's failure to respond  within 90 days to an FDA letter requesting information          |
| more than     | as provided in paragraph (b) of this section. more than                                                           |
| less than     | which the drug is to be developed is less than 200,000 persons, &#8220;prevalence&#8221; is defined as the number |
| after         | development costs that the sponsor expects to incur after  the submission of the designation request.             |
| equal to      | that the total market for the drug is equal to the prevalence of the disease or condition that                    |
| later than    | should preferably be provided in advance, but not later than 60 days after the effective date of such             |
| after         | in advance, but not later than 60 days after  the effective date of such changes.                                 |
| prior to      | at any time in its drug development process prior to the time that sponsor submits a marketing application        |
| within        | sponsor fails to respond to the deficiency letter within 1 year of issuance of the deficiency letter,             |
| within        | sponsor fails to respond to the deficiency letter within 1 year of issuance of the deficiency letter,             |
| after         | request or an orphan-drug designation at any time after the request is submitted or granted, respectively, by     |
| prior to      | (a) At any time  prior to approval of a marketing application for a designated                                    |
| after         | condition; and (e) If the drug loses designation after August 12, 2013, the date of it no                         |
| more than     | disease or condition (or the target population) becomes more than  200,000 persons.                               |
| after         | Within 14 months  after the date on which a drug was designated                                                   |
| after         | Within 14 months  after the date on which a drug was designated                                                   |
| within        | was designated, or for select indication(s) or use(s) within the rare disease or condition for which the          |
| before        | same drug for the same use or indication before the expiration of 7 years from the date                           |
| within        | is limited to only particular indication(s) or uses(s) within the rare disease or condition for which the         |
| within        | is limited to only particular indication(s) or uses(s) within the rare disease or condition for which the         |
| within        | availability of sufficient quantities of the orphan drug within a reasonable time to meet the needs of            |
| before        | of other marketing applications for the same drug before the expiration of the 7-year period of exclusive         |
| within        | (b) If,  within the time that the Director specifies, the holder                                                  |
| prior to      | orphan-drug designation under section 526 of the act prior to final FDA action on the request unless the          |
| prior to      | in the request are available for public disclosure prior to  final FDA action on the request.                     |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7.0 year   | The purpose of this part is to establish standards and procedures for determining eligibility for the benefits provided for in section 2 of the Orphan Drug Act, including written recommendations for investigations of orphan drugs, a 7-year period of exclusive marketing, and treatment use of investigational orphan drugs.                                                                                                                                                         |
| 7.0 year   | (12) Orphan-drug exclusive approval or exclusive approval means that, effective on the date of FDA approval as stated in the approval letter of a marketing application for a sponsor of a designated orphan drug, no approval will be given to a subsequent sponsor of the same drug for the same use or indication for 7 years, except as otherwise provided by law or in this part.                                                                                                    |
| 90.0 day   | (c) Within 90 days after the date of a letter from FDA requesting additional information or material or setting forth the conditions that the sponsor is asked to meet, the sponsor shall either:                                                                                                                                                                                                                                                                                         |
|            |               (1) Provide the information or material or amend the request for written recommendations to meet the conditions sought by FDA; or                                                                                                                                                                                                                                                                                                                                           |
|            |               (2) Withdraw the request for written recommendations.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 90.0 day   | FDA will consider a sponsor's failure to respond within 90 days to an FDA letter requesting information or material or setting forth conditions to be met to be a withdrawal of the request for written recommendations.                                                                                                                                                                                                                                                                  |
| 7.0 year   | (5) A statement of and justification for production and marketing costs that the sponsor has incurred in the past and expects to incur during the first 7 years that the drug is marketed.                                                                                                                                                                                                                                                                                                |
| 7.0 year   | (6) An estimate of and justification for the expected revenues from sales of the drug in the United States during its first 7 years of marketing.                                                                                                                                                                                                                                                                                                                                         |
| 7.0 year   | The justification should include:                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (i) An estimate of the expected market share of the drug in each of the first 7 years that it is marketed, together with an explanation of the basis for that estimate;                                                                                                                                                                                                                                                                                                     |
|            |               (ii) A projection of and justification for the price at which the drug will be sold; and                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (iii) Comparisons with sales of similarly situated drugs, where available.                                                                                                                                                                                                                                                                                                                                                                                                  |
| 60.0 day   | Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes.                                                                                                                                                                                                                                                                                                    |
| 1.0 year   | FDA may consider a designation request voluntarily withdrawn if the sponsor fails to respond to the deficiency letter within 1 year of issuance of the deficiency letter, unless within that same timeframe the sponsor requests in writing an extension of time to respond.                                                                                                                                                                                                              |
| 14.0 month | Within 14 months after the date on which a drug was designated as an orphan drug and annually thereafter until marketing approval, the sponsor of a designated drug shall submit a brief progress report to the FDA Office of Orphan Products Development on the drug that includes:                                                                                                                                                                                                      |
|            |               (a) A short account of the progress of drug development including a review of preclinical and clinical studies initiated, ongoing, and completed and a short summary of the status or results of such studies.                                                                                                                                                                                                                                                              |
| 7.0 year   | Unless FDA previously approved the same drug for the same use or indication, FDA will not approve another sponsor's marketing application for the same drug for the same use or indication before the expiration of 7 years from the date of such approval as stated in the approval letter from FDA, except that such a marketing application can be approved sooner if, and at such time as, any of the following occurs:                                                               |
|            |               (1) Withdrawal of exclusive approval or revocation of orphan-drug designation by FDA under any provision of this part; or                                                                                                                                                                                                                                                                                                                                                   |
|            |               (2) Withdrawal for any reason of the marketing application for the drug in question; or                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (3) Consent by the holder of exclusive approval to permit another marketing application to gain approval; or                                                                                                                                                                                                                                                                                                                                                                |
|            |               (4) Failure of the holder of exclusive approval to assure a sufficient quantity of the drug under section 527 of the act and &#167;&#8201;316.36.                                                                                                                                                                                                                                                                                                                           |
| 7.0 year   | The written notice will inform the sponsor of the requirements for maintaining orphan-drug exclusive approval for the full 7-year term of exclusive approval.                                                                                                                                                                                                                                                                                                                             |
| 7.0 year   | (a) Under section 527 of the act, whenever the Director has reason to believe that the holder of exclusive approval cannot assure the availability of sufficient quantities of an orphan drug to meet the needs of patients with the disease or condition for which the drug was designated, the Director will so notify the holder of this possible insufficiency and will offer the holder one of the following options, which must be exercised by a time that the Director specifies: |
|            |               (1) Provide the Director in writing, or orally, or both, at the Director's discretion, views and data as to how the holder can assure the availability of sufficient quantities of the orphan drug within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated; or                                                                                                                                               |
|            |               (2) Provide the Director in writing the holder's consent for the approval of other marketing applications for the same drug before the expiration of the 7-year period of exclusive approval.                                                                                                                                                                                                                                                                               |


## Condition

| Condition   | Context                                                                                                                                 |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------|
| unless      | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                      |
| when        | 201 of the act apply to those terms when  used in this part.                                                                            |
| where       | will be necessary; or (iii) In unusual cases, where neither greater safety nor greater effectiveness has been                           |
| subject to  | in the manufacture of a drug that is subject to investigation and approval under the act or the                                         |
| if          | designated drug will receive orphan-drug exclusive approval only if the same drug has not already been approved                         |
| if          | same use as the previously approved drug, even if the particular ester or salt (including a salt                                        |
| if          | same use as the previously approved drug, even if the particular ester or salt (including a salt                                        |
| if          | same use as the previously approved drug, even if the particular ester or salt (including a salt                                        |
| if          | use as a previously approved drug, except that, if the subsequent drug can be shown to be                                               |
| if          | use as a previously approved drug, except that, if the subsequent drug can be shown to be                                               |
| if          | criterion will be applied as follows to d if ferent kinds of macromolecules: (A) Two protein drugs                                      |
| unless      | not cause the drugs to be considered different unless  the differences were shown to be clinically superior.                            |
| if          | Two polysaccharide drugs would be considered the same if  they had identical saccharide repeating units, even                           |
| if          | Two polysaccharide drugs would be considered the same if  they had identical saccharide repeating units, even                           |
| if          | Two polysaccharide drugs would be considered the same if  they had identical saccharide repeating units, even                           |
| unless      | vary and even if there were postpolymerization modifications, unless the subsequent drug could be shown to be                           |
| if          | more distinct nucleotides would be considered the same if they had an identical sequence of purine and                                  |
| unless      | backbone (ribose, deoxyribose, or modifications of these sugars), unless the subsequent drug were shown to be clinically                |
| unless      | the same indication, would be considered the same unless the subsequent drug was shown to be clinically                                 |
| if          | to submit information in addition to that spec if ied in paragraph (b) of this section                                                  |
| if          | (4) The generic name and trade name,  if any, of the drug and a list of                                                                 |
| where       | treat a life-threatening or severely debilitating illness, especially where no satisfactory alternative therapy exists, the sponsor may |
| if          | the population from which subjects will be ident if ied for clinical trials,                                                            |
| if          | each proposed United States or foreign clinical investigation, if  available.                                                           |
| if          | investigations necessary for approval of a marketing application if none of the reasons described in &#167;&#8201;316.14 for            |
| when        | studies as described in &#167;&#8201;312.21 of this chapter). when                                                                      |
| if          | insufficient information about: (i) The drug to ident if y the active moiety and its physical and                                       |
| if          | drug for the same rare disease or condition if it can present a plausible hypothesis that its                                           |
| if          | and email address; the generic and trade name, if  any, of the drug, or,                                                                |
| if          | and email address; the generic and trade name, if  any, of the drug, or,                                                                |
| if          | and email address; the generic and trade name, if  any, of the drug, or,                                                                |
| if          | to include the identity of the active moiety if it is a drug composed of small molecules,                                               |
| if          | to include the identity of the active moiety if it is a drug composed of small molecules,                                               |
| if          | to include the identity of the active moiety if it is a drug composed of small molecules,                                               |
| where       | may be clinically superior to the first drug. where                                                                                     |
| where       | be appropriate candidates for use of the drug. where                                                                                    |
| if          | than 200,000 people in the United States or, if the drug is a vaccine, diagnostic drug, or                                              |
| if          | of this part may be referenced by spec if ic page or location                                                                           |
| if          | to whom the drug will be administered annually if the drug is a vaccine or is a                                                         |
| when        | United States, the sponsor shall submit to FDA: when                                                                                    |
| if          | For example,  if the sponsor has incurred costs for clinical investigations,                                                            |
| if          | of this section: (i) Data on and just if ication for all costs that the sponsor has                                                     |
| if          | For example,  if the sponsor charged patients for the drug during                                                                       |
| where       | (3) In cases  where the drug has already been approved for marketing                                                                    |
| where       | (3) In cases  where the drug has already been approved for marketing                                                                    |
| where       | In cases  where the extent of these future development costs are                                                                        |
| where       | (iii) Comparisons with sales of similarly situated drugs, where  available.                                                             |
| where       | (7) The name of each country  where the drug has already been approved for marketing                                                    |
| if          | will send a deficiency letter to the sponsor if the request for orphan-drug designation lacks information required                      |
| if          | FDA may consider a designation request voluntarily withdrawn  if the sponsor fails to respond to the deficiency                         |
| unless      | 1 year of issuance of the deficiency letter, unless within that same timeframe the sponsor requests in                                  |
| if          | FDA will grant the request for orphan-drug designation if none of the reasons described in &#167;&#8201;316.25 for                      |
| when        | publicize the orphan-drug designation in accordance with &#167;&#8201;316.28. when                                                      |
| if          | refuse to grant a request for orphan-drug designation if any of the following reasons apply: (1) The                                    |
| where       | such disease or condition in the United States. where                                                                                   |
| if          | refuse to grant a request for orphan-drug designation if the request for designation contains an untrue statement                       |
| if          | refuse to grant a request for orphan-drug designation if the request for designation contains an untrue statement                       |
| if          | apply for an amendment to the designated use if the proposed change is due to new and                                                   |
| if          | (b) FDA will grant the amendment  if it finds that the initial designation request was                                                  |
| if          | sponsor; (b) The generic name and trade name, if  any, or,                                                                              |
| if          | sponsor; (b) The generic name and trade name, if  any, or,                                                                              |
| if          | sponsor; (b) The generic name and trade name, if  any, or,                                                                              |
| if          | FDA may revoke orphan-drug designation for any drug if the agency finds that: (1) The request for                                       |
| where       | the target population) becomes more than 200,000 persons. where                                                                         |
| if          | is no longer designated in accordance with &#167;&#8201;316.28(e). if                                                                   |
| until       | designated as an orphan drug and annually thereafter until marketing approval, the sponsor of a designated drug                         |
| if          | such a marketing application can be approved sooner if , and at such time as, any of                                                    |
| if          | marketing of another drug, FDA will so not if y the sponsor in writing.                                                                 |
| until       | of the Federal Food, Drug, and Cosmetic Act until the expiration of the period of exclusive marketing                                   |
| if          | will send the sponsor (or, the permanent-resident agent, if applicable) timely written notice recognizing exclusive approval once       |
| if          | will send the sponsor (or, the permanent-resident agent, if applicable) timely written notice recognizing exclusive approval once       |
| when        | date of termination of the orphan-drug exclusive approval. when                                                                         |
| if          | indication, FDA will not recognize orphan-drug exclusive approval if the sponsor fails to demonstrate upon approval that                |
| if          | indication, FDA will not recognize orphan-drug exclusive approval if the sponsor fails to demonstrate upon approval that                |
| if          | If, within the time that the Director spec if ies, the holder fails to consent to the                                                   |
| if          | If, within the time that the Director spec if ies, the holder fails to consent to the                                                   |
| unless      | prior to final FDA action on the request unless the existence of the request has been previously                                        |
| unless      | the use for which the drug was designated unless the existence of the application has been previously                                   |


## Entities

| Entities                                              | Context                                                                                                                                                                                                                      |
|:------------------------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                                                  | Food  and Drugs.                                                                                                                                                                                                             |
| Scope                                                 | Scope  of this part.                                                                                                                                                                                                         |
| Purpose                                               | Purpose .                                                                                                                                                                                                                    |
| Address                                               | Address  for submissions.                                                                                                                                                                                                    |
| Rm                                                    | 32,  Rm .                                                                                                                                                                                                                    |
| United States                                         | Known marketing experience or investigational status outside the United States ; (iii) So far as is known or                                                                                                                 |
| United States                                         | Known marketing experience or investigational status outside the United States ; (iii) So far as is known or                                                                                                                 |
| United States                                         | disease or condition that is rare in the United States , including the following: (i) The size and                                                                                                                           |
| United States                                         | conditions affecting 200,000 or more people in the United States , or for a vaccine, diagnostic drug, or                                                                                                                     |
| United States                                         | conditions affecting 200,000 or more people in the United States , or for a vaccine, diagnostic drug, or                                                                                                                     |
| United States                                         | (15) Detailed protocols for each proposed  United States  or foreign clinical investigation, if available.                                                                                                                   |
| Refusal                                               | Refusal  to provide written recommendations.                                                                                                                                                                                 |
| United States                                         | the disease or condition is rare in the United States ; or (iii) The reasons for believing that                                                                                                                              |
| United States                                         | drug is intended is not rare in the United States .                                                                                                                                                                          |
| Animal                                                | Animal toxicology studies are generally not relevant to a                                                                                                                                                                    |
| United States                                         | and marketing history of the drug in the United States and in foreign countries, e.g., IND and marketing                                                                                                                     |
| United States                                         | intended affects fewer than 200,000 people in the United States or, if the drug is a vaccine, diagnostic                                                                                                                     |
| United States                                         | intended affects fewer than 200,000 people in the United States or, if the drug is a vaccine, diagnostic                                                                                                                     |
| United States                                         | intended affects fewer than 200,000 people in the United States or, if the drug is a vaccine, diagnostic                                                                                                                     |
| United States                                         | intended affects fewer than 200,000 people in the United States or, if the drug is a vaccine, diagnostic                                                                                                                     |
| U.S                                                   | the costs of developing the drug for the U.S . market and the costs of making the                                                                                                                                            |
| United States                                         | costs of making the drug available in the United States .                                                                                                                                                                    |
| United States                                         | defined as the number of persons in the United States who have been diagnosed as having the disease                                                                                                                          |
| United States                                         | To document the number of persons in the  United States who have the disease or condition for which                                                                                                                          |
| United States                                         | recovered by sales of the drug in the United States , the sponsor shall submit to FDA:                                                                                                                                       |
| U.S                                                   | the course of developing the drug for the U.S . market.                                                                                                                                                                      |
| United States                                         | was developed wholly or in part outside the United States , in addition to the documentation listed in                                                                                                                       |
| United States                                         | was developed wholly or in part outside the United States , in addition to the documentation listed in                                                                                                                       |
| U.S                                                   | the course of developing the drug for the U.S . market.                                                                                                                                                                      |
| U.S                                                   | foreign development costs should be applied to the U.S . market, and what percent these costs are                                                                                                                            |
| United States                                         | revenues from sales of the drug in the United States  during its first 7 years of marketing.                                                                                                                                 |
| Cost                                                  | Cost data shall be determined in accordance with generally                                                                                                                                                                   |
| United States                                         | designation shall name a permanent resident of the United States as the sponsor's agent upon whom service of                                                                                                                 |
| Deficiency                                            | Deficiency  letters and granting orphan-drug designation.                                                                                                                                                                    |
| Refusal                                               | Refusal  to grant orphan-drug designation.                                                                                                                                                                                   |
| United States                                         | condition in fewer than 200,000 people in the United States , or that the drug is intended for                                                                                                                               |
| United States                                         | condition in fewer than 200,000 people in the United States , or that the drug is intended for                                                                                                                               |
| United States                                         | condition in fewer than 200,000 people in the United States , or that the drug is intended for                                                                                                                               |
| United States                                         | condition in fewer than 200,000 people in the United States , or that the drug is intended for                                                                                                                               |
| Amendment                                             | Amendment  to orphan-drug designation.                                                                                                                                                                                       |
| Change                                                | Change  in ownership of orphan-drug designation.                                                                                                                                                                             |
| United States                                         | the target population) is under 200,000 in the United States at the time of designation, its designation will                                                                                                                |
| Annual                                                | Annual  reports of holder of orphan-drug designation.                                                                                                                                                                        |
| Scope                                                 | Scope  of orphan-drug exclusive approval.                                                                                                                                                                                    |
| Documents, Government Printing Office, Washington, DC | cumulative supplements is available from the Superintendent of Documents, Government Printing Office, Washington, DC  20402-9325, and is also available online at http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. |
| Treatment                                             | Treatment  use of a designated orphan drug.                                                                                                                                                                                  |
| Guidance                                              | Guidance  documents.                                                                                                                                                                                                         |
| Availability                                          | Availability for public disclosure of data and information in                                                                                                                                                                |


## Date

| Date       | Context                                                                                                                                                 |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2013-08-12 | These postings will contain the following information:                                                                                                  |
|            |               (a) The name and address of the sponsor;                                                                                                  |
|            |               (b) The generic name and trade name, if any, or, if neither is available, the chemical name or a meaningful descriptive name of the drug; |
|            |               (c) The date of the granting of orphan-drug designation;                                                                                  |
|            |               (d) The designated use in the rare disease or condition; and                                                                              |
|            |               (e) If the drug loses designation after August 12, 2013, the date of it no longer having designation.                                     |


